Arrow keys move between marks; Enter selects; F opens full screen.

Skip to content
Procura
Get started
Oasis Diagnostics CorporationReport or remove this logo

Oasis Diagnostics Corporation Federal Contracts

Correct this listing

Doing business as OASIS DIAGNOSTICS CORP

UEIUEI: the 12-character ID the government gives every company registered for federal work. It replaced the DUNS number in April 2022. Glossary F63TP6A99PF3· CAGECAGE code: a 5-character code that identifies one company location for federal work. A company with several sites can have several. Glossary 5XFE6· VANCOUVER, WA· Active registration until Dec 4, 2026· www.4saliva.com (opens in a new tab)

Overview

Buyers and offices that award Oasis Diagnostics prime contracts, US$, active FY2021–FY2026

Obligated since award on contracts active FY2021–FY2026

Click a company to open its profile.

Buyers (sub-agency)OfficesThis companyNational Institutes ofHealth$7.65MNATIONAL INSTITUTES OF HEALTH NHLBI(75N920)$7.65M · National Institutes of Health of…Oasis Diagnostics Corporation$7.65M
Awards toSubcontracts toCircle area = dollars

Insight NATIONAL INSTITUTES OF HEALTH NHLBI (75N920) is its largest buyer. See more on the Buyers tab

1 buying office

Prime contract obligationsObligation: money the government has legally committed to a contract. It is not the same as money paid. Example: $6M obligated of a $10M ceiling. Glossary, FY2021–FY2026

$7.65M

About

From the company's SBA profile, updated Oct 2026

Oasis Diagnostics Corporation develops saliva-based collection and testing technologies for non-invasive specimen analysis. The company manufactures cost-effective tools that collect, stabilize, store, and analyze saliva and urine specimens including proteins, DNA, RNA, cell-free DNA/RNA, exosomes, hormones, drugs of abuse, and metabolites. Oasis technologies serve clinical, laboratory, research, field, and home-based settings across all age groups (infant to geriatric) plus veterinary applications. They enable rapid disease testing, early detection, and biomarker analysis using lateral flow immunoassays, mass spectrometry, next-generation sequencing, ELISA, and other laboratory techniques. Key differentiators include proprietary purification processes producing clean specimens for immediate testing and advanced in-vitro diagnostic substance manufacturing. and broad accessibility across diverse testing environments.

Prime contract obligations by fiscal year, US$, FY2021–FY2026

Agencies report with a delay; the latest year will rise

Hover over a year to see its value.

FY21$7.68MFY22FY23FY24FY25−$24.7K

Insight Largest year: $7.68M in FY2021. See more on the Contracts tab

Prime obligations since award by state of performance, US$, contracts active FY2021–FY2026

Click a state to open its page.

AKMEVTNHWAIDMTNDMNILWIMINYRIMAORNVWYSDIAINOHPANJCTCAUTCONEMOKYWVVAMDDEAZNMKSARTNNCSCDCOKLAMSALGAHITXFLPR
  1. Washington$7.65M · 100%
Circle area = dollarsOutlined: head office state (Washington)

Insight 100% was performed in Washington. See more on the Contracts tab